RFC and MTHFR SNPs & hENT1- dCK Expression as Prognostic Factors in ALL & hENT1- dCK Expression as Prognostic Factors in AML
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01307241|
Recruitment Status : Unknown
Verified November 2013 by DR. MYRNA CANDELARIA, National Institute of Cancerología.
Recruitment status was: Active, not recruiting
First Posted : March 2, 2011
Last Update Posted : November 15, 2013
|Condition or disease|
|Acute Lymphoblastic Leukemia. Acute Myeloblastic Leukemia|
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||Evaluation of RFC Transporter & MTHFR SNP's, as Well as hEN1 and DCK Expression as Prognostic Factors in Patients With Acute Lymphoblastic Leukemia.|
|Study Start Date :||December 2010|
|Estimated Primary Completion Date :||December 2014|
|Estimated Study Completion Date :||December 2015|
Adult patients with ALL attending at the Instituto Nacional de Cancerologia Mexico.
- To evaluate clinical response [ Time Frame: December 2012 ]To evaluate clinical response after ending Hyper-CVAD schema for ALL patients. To evaluate clinical response & DFS in relation with hENT1 & dCK expression levels in AML patients.
- Clinical responses in relation with SNP's or gene expression [ Time Frame: clinical response. ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01307241
|Instituto Nacional de Cancerologia|
|Mexico city, DF, Mexico, 14080|
|Principal Investigator:||myrna candelaria, md||Instituto Nacional de Cancerología Mexico|